Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Taxes (2017 - 2019)

Avalo Therapeutics' Current Taxes history spans 3 years, with the latest figure at $551671.0 for Q4 2019.

  • For Q4 2019, Current Taxes fell 72.85% year-over-year to $551671.0; the TTM value through Dec 2019 reached $551671.0, down 72.85%, while the annual FY2019 figure was $551671.0, 72.85% down from the prior year.
  • Current Taxes reached $551671.0 in Q4 2019 per AVTX's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $3.2 million in Q3 2017 to a low of $551671.0 in Q4 2019.
  • Average Current Taxes over 3 years is $1.9 million, with a median of $2.1 million recorded in 2018.
  • Peak YoY movement for Current Taxes: decreased 10.04% in 2018, then tumbled 72.85% in 2019.
  • A 3-year view of Current Taxes shows it stood at $2.3 million in 2017, then fell by 10.04% to $2.0 million in 2018, then crashed by 72.85% to $551671.0 in 2019.
  • Per Business Quant, the three most recent readings for AVTX's Current Taxes are $551671.0 (Q4 2019), $1.0 million (Q3 2019), and $1.4 million (Q2 2019).